Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
Wolff
Antonio C
AC
Davidson
Nancy E
NE
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000209:etiology*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008594:Menopause, Premature; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010053:Ovary / Q000528:radiation effects*; D017697:Premenopause; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen